A pilot randomized trial comparing CD34‐selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis

Abstract

HSCT can be performed safely in patients with RA, and initial results indicate significant responses in patients with severe, treatment-resistant disease. Similar outcomes were observed in patients undergoing HSCT with unmanipulated cells and those receiving CD34-selected cells. Larger studies are needed to confirm these findings.